The Chemours Company (CC) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for April 24, 2026, with virtual participation and voting on key proposals.

• Board leadership transitioned in September 2025, with a new Chair and Lead Independent Director, and continued focus on long-term strategy and shareholder value.

• 2025 saw disciplined execution of the Pathway to Thrive (PTT) strategy, emphasizing operational excellence, growth in high-potential sectors, and portfolio optimization.

• Financial results for 2025 included $5.8 billion in net sales, $742 million in adjusted EBITDA, and significant cost savings, despite macroeconomic headwinds.

• Management resolved legacy liabilities, advanced sustainability goals, and maintained active shareholder engagement.

Voting matters and shareholder proposals

• Election of eleven director nominees for one-year terms.

• Advisory vote on executive compensation (say-on-pay).

• Approval of the 2026 Equity and Incentive Plan to maintain competitive equity compensation.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.

Board of directors and corporate governance

• Board comprises 11 members, 10 of whom are independent; all committees are fully independent.

• Board refreshment and succession planning continued, with new directors added each year for five years.

• Board and committee self-evaluations and peer assessments conducted annually.

• Board diversity: 45% gender diverse, one director from an underrepresented community.

• Board leadership structure separates Chair and Lead Independent Director roles.